InvestingPro Fair Value analysis captures 67% gain on Certara stock

On April 1, 2026, the InvestingPro Fair Value analysis identified a significant opportunity in Certara, Inc. (NASDAQ:CERT) that many investors had missed. The stock, trading at $5.48, was deemed undervalued by the analysis, which predicted a potential 51.46% upside. Six months later, Certara's stock had surged to $9.37, resulting in a remarkable 66.61% gain.

This success highlights how Fair Value analysis can uncover better entry points and intrinsic stock worth, enabling more informed investment decisions. Certara specializes in life sciences technology, offering biosimulation software and services to assist pharmaceutical and biotech companies in optimizing drug development. Despite a challenging six-month period marked by a 21% monthly decline, the Fair Value analysis highlighted Certara's strengths.

These included a new CEO with commercial expertise, a strong position in a fragmented market, projected 21% EPS growth, and a robust 13% free cash flow yield. The company's strategic moves, such as a partnership with Nvidia to integrate AI agents into its platform, were also undervalued by the market. The Fair Value analysis calculated Certara's intrinsic worth at $8.30, suggesting a significant 51.46% upside.

The analysis proved accurate as Certara shares continued to climb, reaching $9.37 by October 9, 2026. The Fair Value methodology proved its worth by looking beyond short-term noise to identify the stock's true value, even as the company missed EPS forecasts in Q1 and Q2 of 2026. Recent developments, including the sale of its regulatory writing unit to Veristat for $135 million and a partnership with Nvidia, have further validated the Fair Value analysis's bullish thesis.

Certara's stock is still trading below its intrinsic worth of $12.05, indicating an additional 28.6% upside potential.